Second malignant neoplasms in pediatric oncology patients: A single center experience
Gazi Medical Journal, ISSN: 2147-2092, Vol: 28, Issue: 3, Page: 164-167
2017
- 5Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures5
- Readers5
Article Description
Objective: The pediatric malignancy survival rate has increased with new and intensive treatment modality advancements. This has led to an approximately 70% chance of surviving more than 5 years in children diagnosed with cancer. However, the secondary tumor incidence has also increased with these advances. The patient's quality of life, late side effects, and prevention of secondary malignancies in the future are as important as treating the primary tumor in pediatric cancer patients. Methods: We retrospectively evaluated the charts of 2100 pediatric cancer patients who were diagnosed in our clinic between 1985 and 2012. Results: There were 11 secondary tumors. Male-To-female ratio was 6:5 and median age at diagnosis was 7 years (range, 1 year 3 months-11 years 6 months). Secondary tumor diagnosis was AML in five patients, paraganglioma in one patient, liposarcoma in one patient, rhabdomyosarcoma in one patient, papillary thyroid carcinoma in one patient, malignant fibrous histiocytoma in one patient, and squamous cell carcinoma of the tongue in one patient. AML was the most commonly detected secondary malignancy. Conclusion: We suggest that using less toxic systemic chemotherapy and reduced-dose radiotherapy is increasingly important with targeted treatment modalities to decrease the risk of secondary malignancy.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know